This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice.
Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA’s) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.
Foreign Organizations
- Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
- Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
- Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Visit funding web page
(https://grants.nih.gov/grants/guide/pa-files/PAR-25-209.html)
